| Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy R Seiler, HAD Ashab, N Erho, BWG van Rhijn, B Winters, J Douglas, ... European urology 72 (4), 544-554, 2017 | 753 | 2017 |
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 558 | 2020 |
| Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial T Powles, M Kockx, A Rodriguez-Vida, I Duran, SJ Crabb, ... Nature medicine 25 (11), 1706-1714, 2019 | 474 | 2019 |
| Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer KJ Pienta, JP Machiels, D Schrijvers, B Alekseev, M Shkolnik, SJ Crabb, ... Investigational new drugs 31, 760-768, 2013 | 400 | 2013 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 382 | 2020 |
| Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group G Ryan, G Martinelli, M Kuper-Hommel, R Tsang, G Pruneri, K Yuen, ... Annals of Oncology 19 (2), 233-241, 2008 | 327 | 2008 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 239 | 2017 |
| Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised … G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ... The lancet 399 (10323), 447-460, 2022 | 221 | 2022 |
| IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre … BI Rini, A Stenzl, R Zdrojowy, M Kogan, M Shkolnik, S Oudard, S Weikert, ... The Lancet Oncology 17 (11), 1599-1611, 2016 | 217 | 2016 |
| Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer SJ Crabb, MCU Cheang, S Leung, T Immonen, TO Nielsen, ... Clinical breast cancer 8 (3), 249-256, 2008 | 199 | 2008 |
| Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer MD Galsky, SK Pal, S Chowdhury, LC Harshman, SJ Crabb, YN Wong, ... Cancer 121 (15), 2586-2593, 2015 | 192 | 2015 |
| Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor … T Powles, RA Huddart, T Elliott, SJ Sarker, C Ackerman, R Jones, ... Journal of Clinical Oncology 35 (1), 48-55, 2017 | 190 | 2017 |
| EAU-ESMO Consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort†: under the auspices of the EAU … JA Witjes, M Babjuk, J Bellmunt, HM Bruins, TM De Reijke, M De Santis, ... European urology 77 (2), 223-250, 2020 | 166 | 2020 |
| Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non–small-cell lung cancer SJ Crabb, D Patsios, E Sauerbrei, PM Ellis, A Arnold, G Goss, NB Leighl, ... Journal of Clinical Oncology 27 (3), 404-410, 2009 | 166 | 2009 |
| Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib C Lolli, U Basso, L Derosa, E Scarpi, T Sava, M Santoni, SJ Crabb, ... Oncotarget 7 (34), 54564, 2016 | 153 | 2016 |
| Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors H Benelkebir, C Hodgkinson, PJ Duriez, AL Hayden, RA Bulleid, ... Bioorganic & medicinal chemistry 19 (12), 3709-3716, 2011 | 139 | 2011 |
| S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase … A Hayden, PWM Johnson, G Packham, SJ Crabb Breast cancer research and treatment 127, 109-119, 2011 | 129 | 2011 |
| Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery A Ganesan, L Nolan, SJ Crabb, G Packham Current Cancer Drug Targets 9 (8), 963-981, 2009 | 129 | 2009 |
| Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? L Nolan, PWM Johnson, A Ganesan, G Packham, SJ Crabb British journal of cancer 99 (5), 689-694, 2008 | 106 | 2008 |
| The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer A Hayden, J Douglas, M Sommerlad, L Andrews, K Gould, S Hussain, ... Urologic Oncology: Seminars and Original Investigations 32 (6), 806-814, 2014 | 103 | 2014 |
Graham PackhamUniversity of SouthamptonVerified email at soton.ac.uk
